CClinicalTrials.gg
RecruitingNCT03141021Updated Mar 9, 2026

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

An observational study in Malignant Peripheral Nerve Sheath Tumors, sponsored by Washington University School of Medicine. Recruiting at 13 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Washington University School of Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,050
Sex
All
01

Study summary

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.

02

Conditions studied

  • Malignant Peripheral Nerve Sheath Tumors

Browse trials for

03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The oncology clinic of each participating institution

Eligibility criteria

Inclusion Criteria and Exclusion Criteria:

-Any patient diagnosed with an MPNST is eligible for enrollment to this registry provided s/he consents to participate (or consent form his/her parent or legal guardian or legally authorized representative is obtained).

04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,050 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
05

What researchers measure

Primary outcomes

  1. Histologic characteristics of malignant peripheral nerve sheath tumor (MPNST)

    -The data collected through this registry will be used to analyze previously unanticipated patterns and prognostic clues about MPNST

    Time frame: 10 years

  2. Immunohistochemical characteristics of malignant peripheral nerve sheath tumor (MPNST)

    -The data collected through this registry will be used to analyze previously unanticipated patterns and prognostic clues about MPNST

    Time frame: 10 years

  3. Molecular characteristics of malignant peripheral nerve sheath tumor (MPNST)

    -The data collected through this registry will be used to analyze previously unanticipated patterns and prognostic clues about MPNST

    Time frame: 10 years

  4. Radiographic characteristics of malignant peripheral nerve sheath tumor (MPNST)

    -The data collected through this registry will be used to analyze previously unanticipated patterns and prognostic clues about MPNST

    Time frame: 10 years

  5. Treatment given to patients with malignant peripheral nerve sheath tumor (MPNST)

    -The data collected through this registry will be used to analyze previously unanticipated patterns and prognostic clues about MPNST

    Time frame: 10 years

  6. Future genomic characterization of malignant peripheral nerve sheath tumor (MPNST)

    -The data collected through this registry will be used to analyze previously unanticipated patterns and prognostic clues about MPNST

    Time frame: 10 years

06

Study locations

4 of 13 sites recruiting
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Completed
  • Johns Hopkins
    Baltimore, Maryland 21205, United States
    • Christine Pratilas, M.D. · Contact · 410-955-8751
    • Christine Pratilas, M.D. · Principal investigator
    Recruiting
  • National Institutes of Health (NIH)
    Bethesda, Maryland 20892, United States
    • Jack F Shern, M.D. · Contact · john.shern@nih.gov · 301-402-1444
    • Jack F Shern, M.D. · Principal investigator
    Not yet recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Withdrawn
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Withdrawn
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    • Angela Hirbe, M.D., Ph.D. · Contact · hirbea@wustl.edu · (314) 362-8965
    • Angela Hirbe, M.D., Ph.D. · Principal investigator
    • David Gutmann, M.D., Ph.D. · Sub investigator
    • Sonika Dahiya, M.D., MBBS · Sub investigator
    • Brian Van Tine, M.D., Ph.D. · Sub investigator
    • Peter Oppelt, M.D. · Sub investigator
    Recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    • Ping Chi, M.D., Ph.D. · Contact · 646-888-4166
    • Ping Chi, M.D., Ph.D. · Principal investigator
    Not yet recruiting
  • Lifespan
    Providence, Rhode Island 02903, United States
    Completed
  • University of Utah
    Salt Lake City, Utah 84112, United States
    Completed
  • Mount Sinai
    Toronto, Ontario M5T 3L9, Canada
    Recruiting
  • Global Gene Corporation
    Mumbai, India
    Completed
  • Nagoya University Hospital
    Nagoya, Showa Ward, Japan
    • Yoshihiro Nishida, M.D., Ph.D. · Contact · ynishida@med.nagoya-u.ac.jp · +81 52-741-2111
    • Yoshihiro Nishida, M.D., Ph.D. · Principal investigator
    Recruiting
  • Royal National Orthopedic Hospital
    London, United Kingdom
    Terminated
07

References and documents

08

Registry details

Key details

Study ID
NCT03141021
Lead sponsor
Washington University School of Medicine
Collaborators
Boston Children's Hospital
Responsible party
Sponsor
First posted
May 4, 2017
Start date
Apr 28, 2017
Primary completion
Apr 30, 2053 (estimated)
Completion
Apr 30, 2053 (estimated)
Last update
Mar 9, 2026

Study contacts

Angela Hirbe, M.D., Ph.D.
Contact
hirbea@wustl.edu
(314) 362-8965
Angela Hirbe, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion